Evaluation and treatment of resistant hypertension

Cardiology Journal

Volumn 14, Issue 4, 2007, Pages 329-339

  Sloand, James A ^a   Balakrishnan, Sangeetha L ^a   Fong, Michael W ^a   Bisognano, John D ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Etiology; Resistant hypertension; Treatment

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; AMILORIDE; AMPHETAMINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; COCAINE; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRINE; ESTROGEN; GADOLINIUM; GINKGO BILOBA EXTRACT; HEMATOLOGIC AGENT; HYPERICUM PERFORATUM EXTRACT; LOOP DIURETIC AGENT; MINOXIDIL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOXYBENZAMINE; POTASSIUM; PROGESTERONE; PSEUDOEPHEDRINE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADENOMA; ANTHROPOMETRIC PARAMETERS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG MEGADOSE; EDEMA; ENDOCRINE DISEASE; ENDOCRINE SURGERY; HEART FAILURE; HIRSUTISM; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; LIFESTYLE; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROTOXICITY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 34648825541     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA, 2003; 290: 199-206.
2. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA, 2005; 294: 1255-1259.
3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360: 1903-1913.
4. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and the risk of end stage renal disease in subjects without baseline kidney disease. Arch Intern Med, 2005; 165: 923-928.
5. United States Renal Data System, 2005.
6. Cooper RS, Liao Y, Rotimi C. Is hypertension more severe among U.S. blacks, or is Severe hypertension more common? Ann Epidemiol, 1996; 6: 173-180.
7. Burt VL, Whelton P, Roccella EJ et al. Prevalence of Hypertension in the US Adult Population: Results From the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertens, 1995; 25: 305-313.
8. Berenson GS, Voors AW, Weber LS et al. Racial differences of parameters associated with blood pressure levels in children: the Bogalusa Heart Study. Metabolism, 1979; 28: 1218-1228.
9. Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens, 1996; 14: 935-941.
10. Profant J, Dimsdale JE. Race and diurnal blood pressure patterns: a review and meta-analysis. Hypertension, 1999; 33: 1099-1104.
11. Wilson DK, Sica DA, Miller SB. Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents. Am J Hypertens, 1999; 12: 159-165.
12. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC Report. JAMA, 2003; 289: 2560-2572.
13. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care, 2006; 29 (suppl. 1): S4-S42.
14. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. AJKD, 2004; 43 (suppl. 1): 65-230.
15. Gifford RW Jr. Resistant hypertension: Introduction and definitions. Hypertension, 1988; 11: 65-66.
16. Swales JD, Bing RF, Heagerty A. Treatment of refractory hypertension. Lancet, 1982; 1: 894-896.
17. Muxfeldt ES, Bloch KV Nogueira AR et al. Twenty four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit, 2003; 8: 181-185.
18. Beevers G, Lip GY, O'Brien E. ABC of Hypertension. Blood press measurement. Part I. Sphygmomanometry: Factors common in all techniques. BMJ, 2001; 322: 981-985.
19. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: blood pressure measurement in humans: A statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension, 2005; 45: 142-161.
20. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Vegho F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab, 2005: 16: 114-119.
21. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-394.
22. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: Diagnostic accuracy of the ratio of plasma aldosterone concentration to PRA. Clin Chem, 2005; 51: 386-394.
23. Pimenta E, Calhoun DA. Primary Aldosteronism: Diagnosis and treatment. J Clin Hypertens, 2006; 8: 887-893.
24. Mattsson C, Young WF. Primary aldosteronism: Diagnostic and treatment strategies. Nature Clin Pract, 2006; 2: 198-208.
25. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab, 1971; 33: 14-22.
26. Yaneva M, Mosnier-Pudar H, Duque MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab, 2004; 89: 3345-3351.
27. Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab, 2002; 87: 4515-4521.
28. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol, 1995; 43: 545-550.
29. Blethen SL, Chasalow FI. Overnight dexamethasone suppression test: normal responses and the diagnosis of Cushing's syndrome. Steroids, 1989; 54: 185-193.
30. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethazone suppression test to screen for Cushing's syndrome: Recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem, 1997; 34: 222-229.
31. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med, 2003; 13: 980-991.
32. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetic, diagnostics, localization, and treatment of pheochromocytoma. Ann Intern Med, 2001; 134: 315-329.
33. Eisenhofer G, Huysmana F, Pacak K, Walther MM, Sweep FC, Lenders JW. Plasma metanephrines in renal failure. Kidney Int, 2005; 67: 668-677.
34. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab, 2003; 88: 2656-2666.
35. Vasbinder GBC, Nelemans PJ, Kessels AGH et. al. Accuracy of computer angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med, 2004; 141: 674-682
36. Alhaddad IA, Blum S, Heller EN et al. Renal artery stenosis in minority patients undergoing diagnostic cardiac catheterization: Prevalence and risk factors. J Cardiovasc Pharmacol Ther, 2001; 6: 147-153.
37. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme Iinhibitor therapy. Circulation, 2001; 104: 1985-1991.
38. Tullis MJ, Caps MT, Zierler RE et al. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis, 1999; 33: 675-681.
39. Schoenberg SO, Rieger J, Johannson LO, Dietrich O, Prince MR, Reise MF. Diagnosis of renal artery stenosis with magnetic resonance angiography: update 2003. Nephrol Dial Transplant, 2003; 18: 1252-1256.
40. Riehl J, Schmitt H, Bongartz D, Bergmann D, Sieberth HG. Renal artery stenosis: Evaluation with color duplex ultrasound. Nehrol Dial Transplant, 1997; 12: 1608-1614.
41. Garovic VD, Kane GC, Schwartz GL. Renovascular hypertension: Balancing the controversies in diagnosis and treatment. Cleveland Clin J Med, 2005; 72: 1135-1147.
42. Elkohen M, Beregi JP, Deklunder G et al. A prospective study of helical computed tomography angiography versus angiography for the detection of renal artery stenosis in hypertensive patients. J Hypertens, 1996; 14; 525-528.
43. www.fda.gov/cder/drug/advisory/gadolinium_agents (Dec 2006).
44. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Eng J Med, 2006; 354: 379-386.
45. Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med, 2004; 350: 1862-1871.
46. Prisant LM, Szerlip HM, Mulloy LL. Fibromuscular dysplasia: An uncommon cause of secondary hypertension. J Clin Hypertens, 2006; 8: 894-898.
47. Galla JH, Luke RG. Hypertension in renal parenchymal disease. In: Brenner BM ed. Brenner and Rector's the kidney. 6th ed. W.B. Saunders, Philadelphia 2000: 2035-2058.
48. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension, 2004: 43: 699-706.
49. Oates JA. Antagonism of antihypertensive drug therapy by nonsteroidal anti-inflammatory drugs. Hypertension, 1988; 11 (suppl. II): 4-6.
50. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens, 2001; 14: 971-975.
51. The ALLHAT Officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002; 288: 2981-2997.
52. Graves JW, Bloomfield RL, Buckalew VM. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci, 1989; 298: 361-365.
53. Altura BM, Altura BT Peripheral and cerebrovascular actions of ethanol, acetaldehyde, and acetate: Relationship to divalent cations. Alcoholism Clin Exper Res, 1987; 11: 99-111.
54. Randin D, Vollenweider P, Tappy L, Jequier E, Nicod P, Scherrer U. Suppression of alcohol-induced hypertension by dexamethasone. NEJM, 1995; 332: 1733-1738.
55. Richert A, Anasarin K, Baran AS. Sleep apnea and hypertension: pathophysiologic mechanisms. Semin Nephrol, 2002; 22: 71-77.
56. Pickering TG. Sleep apnea and hypertension. J Clin Hypertens, 2002; 4: 437-440.
57. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest, 2006; 129: 1459-1467.
58. James PT, Leach R, Kalamara E, Shayegi M. The worldwide obesity epidemic. Obes Res, 2001; supl. 9: 228S-233S.
59. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension, and progressive renal disease. J Am Soc Nephrol, 2004; 15: 2816-2827.
60. Rahmouni K, Correia LG, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension, 2005; 45: 9-14.
61. Izzo JL. Sympathoadrenal activity, catecholamines, and the pathogenesis of vasculopathic hypertensive target-organ damage. Am J Hypertens, 1989; 2: 305S-312S.
62. Gareth B, Lip GYH, O'Brien E. The ABC of Hypertension: The pathophysiology of hypertension. BMJ, 2001; 322: 912-916.
63. Materson BJ, Reda DJ, Cushman WC et al. Single--drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. NEJM. 1993; 328: 914-921.
64. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet, 2003; 361: 117-124.
65. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet, 2003; 362: 759-766.
66. Sica D. Combination calcium channel blocker therapy in the treatment of hypertension. J Clin Hypertens, 2001; 3: 322-327.
67. Stason WB, Shepard DS, Perry HM et al. Effectiveness and costs of veterans affairs hypertension clinics. Med Care, 1994; 32: 1197-215.
68. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112: 1651-1662.
69. Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab, 2005; 19: 567-575.
70. Calhoun DA. Aldosterone and hypertension. Clin J Am Soc Nephrol, 2006; 1: 1039-1045.
71. Kirchengast M, Luz M. Endothelin receptor antagonists: Clinical realities and future directions. J Cardiovasc Pharmacol, 2005; 45: 182-191.
72. Vorobiof G, Blaxall BC, Bisognano JD. The future of endothelin-receptor antagonism as treatment for systemic hypertension. Curr Hypertens Rep, 2006; 8: 35-44.
73. Filippone JD, Sloand JA, Illig KA, Bisognano JD. Electrical stimulation of the carotid sinus for the treatment of resistant hypertension. Curr Hypertens Rep, 2006; 8: 420-424.
74. Bisognano J, Sloand J, Papademetriou V et al. An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multi-center Rheos Feasibility Trial. Circulation, 2006; 575 (suppl. II): 2751.
75. Grossman E, Grossman A, Schein MH, Zimlichman R, Gavish B. Breathing control lowers blood pressure. J Human Hypertens, 2001; 15: 263-269.
76. Rosenthal T, Alter A, Peleg E, Gavish B. Device--guided breathing exercises reduce blood pressure: Ambulatory and home measurements. Am J Hypertens, 2001; 14: 74-76.
77. Viskoper R, Shapira, Priluck I et al. Non-pharmacological treatment of resistant hypertensives by device-guided slow breathing exercises. Am J Hypertens, 2003; 16: 484-487.
78. Schein M, Gavish B, Herz M et al. Treating hypertension with a device that slows and regularizes breathing: A randomized double-blind controlled study. J Human Hypertens, 2001; 15: 271-2780
79. Elliott WJ, Izzo JL Jr, White WB et al. Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing. J Clin Hypertens, 2004; 6: 553-559.
80. Grassi D, Necozione S, Lippi C et al. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension, 2005; 46: 398-405.